Mar 04, 2021 / 07:10PM GMT
Kenneth Charles Cacciatore - Cowen and Company, LLC, Research Division - MD & Senior Research Analyst
Okay. Great. Thanks, everyone, for joining the Aurinia fireside. We're really happy to have today with us Peter, Neil, Max and Glenn. Thanks for taking the time. You're in the midst of real busy time, exciting time for the company with the launch. So we're appreciative of having you guys for at least a half an hour here.
With that, Peter, why don't we turn it over to you see if you have any opening comments or thoughts?
Peter S. Greenleaf - Aurinia Pharmaceuticals Inc. - President, CEO & Director
Ken, first and foremost, on behalf of the company, I want to thank Cowen and yourself and your team for having us here today. Obviously, it's an exciting time for the company. I mean we've gone through the last 2 years pushing our way through Phase III data and a positive outcome in our lupus nephritis trial after years of work, post the acquisition of the asset from the original founders of the company. And that rolled into a busy year of NDA filing,
Aurinia Pharmaceuticals Inc at Cowen Healthcare Conference (Virtual) Transcript
Mar 05, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers